Patient-Friendly Explanation
Rybelsus is a daily tablet version of semaglutide for people with type 2 diabetes. It offers an oral alternative to injections.
Clinical Definition
Rybelsus is the first oral GLP-1 receptor agonist, containing semaglutide with an absorption enhancer. It is indicated for type 2 diabetes at doses of 3 mg, 7 mg or 14 mg daily. It is a prescription-only medicine.